How will independent prescribing work in Pharmacy First?

What was announced on 29 May 2026?

On 29 May 2026 the Department of Health and Social Care (DHSC), NHS England and Community Pharmacy England (CPE) announced the 2026/27 Community Pharmacy Contractual Framework. It includes the first NHS-funded independent prescribing service for community pharmacies in England. The government's own summary calls it "a national NHS IP offer", introduced from autumn 2026 as an extension of Pharmacy First and the Pharmacy Contraception Service.

The wider settlement puts total funding at £3.636bn for 2026/27. That is a rise of £340m, or 10.3 per cent, on 2025/26. The single activity fee rises by 6p to £1.52, backdated to May 2026, and other fees stay where they are. For the full package, see what the 2026/27 contract actually pays.

For Pharmacy First, this is the biggest change since the service launched on 31 January 2024. Until now, pharmacists have supplied medicines under patient group directions (PGDs). A PGD fixes the medicine, the dose and the inclusion criteria in advance. A prescriber can assess the patient and prescribe directly, within their own competence. The DHSC press release says qualified pharmacists "will assess patients and prescribe medicines directly". The same release reports 3.3 million Pharmacy First consultations between March 2025 and February 2026, up 43 per cent on the previous year.

CPE accepted the deal but did not hide its doubts. In its statement on 29 May it said it was "not persuaded that sufficient investment is being made to enable the full and effective introduction of IP within the CPCF". It had warned during talks that, at the proposed funding, adding prescribing "risked being set up to fail". The Pharmacists' Defence Association called the change "a significant further increase in clinical responsibility", not a minor extension. David Webb, England's Chief Pharmaceutical Officer, said community pharmacists "will for the first time be able to prescribe NHS medicines across a range of health conditions as a nationally commissioned service".

What will pharmacist prescribers be able to prescribe?

Three things, according to CPE's briefing 009/26. Prescribers will be able to prescribe within the existing Pharmacy First clinical pathways and the contraception service. They will be able to provide up to five new prescribing-only pathways. And they will be able to prescribe an alternative item where a supply problem affects a patient's original prescription. The table below sets out each strand, with the fees taken from the DHSC summary of the settlement.

The first strand matters most for volume. The seven pathways already generate millions of consultations a year, and the prescriber version pays the same £17. What changes is the clinical latitude. Under a PGD the pharmacist can only supply the listed medicine to a patient who meets every criterion. A prescriber can treat the patient in front of them. How much latitude each pathway will allow is not yet public, because NHS England has not published the prescribing versions of the clinical protocols.

The contraception strand follows the same logic. The PGD-based service already covers initiation, ongoing supply and, since 29 October 2025, oral emergency contraception. A prescriber can go beyond the PGD's fixed product list where it is clinically right to do so.

The supply-problem strand is narrower than it sounds. CPE's wording is an alternative item "where there is a supply chain issue relating to the original prescription, and there are arrangements in place with the original prescriber". That last clause means a local agreement with the GP practice, not a general power to switch medicines. It sits alongside the Serious Shortage Protocol route, which needs no prescriber at all.

What are the five prescribing-only pathways?

Nothing is confirmed. CPE's briefing lists five "options to be considered": bacterial conjunctivitis, allergic conjunctivitis, oral thrush, skin infections and respiratory tract infections. The DHSC summary says "up to 5 new prescribing-only pathways subject to assessment by a clinical reference group". So the final number could be lower than five, and the conditions could change.

Each is a common condition that GP practices see in volume. None can be handled under the current Pharmacy First pathways, because there is no PGD for them. Only a prescriber can complete the episode of care. That is why these pathways are "prescribing-only": a pharmacy without a prescriber cannot offer them, and will only be able to advise or refer.

New pathway consultations will be paid at £17, the same as the existing pathways, and will count towards the monthly minimum activity requirement. We are tracking the clinical reference group's work in a separate piece on the five new Pharmacy First prescribing pathways. We will update it as details are published.

Who can deliver the service?

Only a pharmacist with an independent prescriber annotation on the GPhC register, working in a pharmacy that has signed up. The question for owners is how many of those pharmacists work in community pharmacy, and the answer is: not many yet. The table below uses the two most recent published counts.

So a third of the profession can prescribe, but most of those prescribers work in hospitals and general practice. Community pharmacy had about one prescriber for every five premises in 2024. The same survey found that most community prescribers were not using the qualification. The pipeline is about to change, though. The GPhC said on 10 June 2026 that "the majority of pharmacists joining the GPhC register from summer 2026 will be independent prescribers from the point of registration". The first cohort trained under the 2021 education standards sits the registration assessment on 16 June 2026, with results due on 21 July.

Newly qualified prescribers will still need to prescribe within their competence, and the GPhC's advice leans heavily on employers to provide supervision and support. If you are an experienced pharmacist wanting the annotation, the route is a GPhC-accredited course with a designated prescribing practitioner. We cover the options in how to become a pharmacist independent prescriber.

Nothing published so far says whether a locum prescriber can deliver the service on a pharmacy's behalf. The sign-up sits with the pharmacy owner, and the clinical governance requirements will come through changes to the Terms of Service. Until those are published, treat the locum question as open.

What does the NHS pay?

Two new payments, plus the existing consultation fees. The figures below come from the DHSC summary and CPE's briefing 009/26.

Over a full year the infrastructure payment is worth £6,300, or £6,800 in the first year with the set-up fee. That is the sum CPE says is not enough. Its argument during negotiations was that prescribing consultations should attract a higher fee than PGD consultations, because the clinical governance and infrastructure costs are higher. It did not win that point: the consultation fees match the PGD services exactly.

The consequence is simple. The payments cover some infrastructure, but not a prescriber's time. Whether the service pays depends on whether you already employ a prescriber and how many consultations you can move to them. We work through that arithmetic in should your pharmacy offer the new NHS prescribing service.

How do the caps and thresholds change?

Prescribing consultations count towards the Pharmacy First fixed payment, and each cap band gets a second, higher limit for prescribing pharmacies. The DHSC summary says fixed payments "will remain at £500 for contractors delivering 20 to 29 consultations" and £1,000 for 30 or more. New IP clinical pathway consultations count towards those thresholds, so a prescriber's consultations help you reach the £1,000 month in the same way a PGD consultation does.

The caps on the number of consultations paid to high-volume pharmacies stay for 2026/27. CPE's briefing explains the mechanism: "two caps within each band: one applicable to pharmacies signed up to provide prescribing services, and one for those who are not". The DHSC version describes it as "an additional allowance made to each capping band" for contractors delivering prescribing consultations. In other words, prescribing pharmacies can be paid for more consultations before hitting the cap. The exact numbers per band have not been published.

Two other changes touch the same services. Pharmacy First, hypertension case-finding and the contraception service stay bundled, so you must still be registered for all three. And the claim window is changing: the one-month window for Pharmacy First and NMS stays, but a late-claims process will accept submissions for up to two months after it closes. CPE says that gives owners three months in total, and will confirm the implementation date. See the three-month claim window for the detail.

Do you have to take part, and how do you sign up?

No, the service is optional. CPE's words are: "It will be down to pharmacy owners to decide on an individual basis whether they want to provide the service". The alternative, in CPE's phrase, is to "prioritise the use of IP skills elsewhere in their business". A pharmacy that does not sign up keeps delivering the PGD-based services as now, under the standard cap.

The sign-up process itself has not been published. What we know is the trigger for the £500. The owner must have signed up to provide the relevant services and have a confirmed go-live date with an NHS-assured Electronic Prescription Service IT system. In practice that means the clinical system you use for consultations must be able to create electronic prescriptions, not just receive them. Ask your system supplier now whether, and when, it will be assured for community pharmacy prescribing.

What is still to be published?

Most of the operational detail. As of mid-June 2026, the announcement gives the shape of the service and the money, but not the documents you would need to run it. CPE says: "Further information will be published ahead of the go-live date in the autumn".

That last item matters more than it looks. Integrated care boards will be the bodies checking that a pharmacy's prescriber is competent, supervised and indemnified before it goes live. How they do that, and how quickly, will decide whether "autumn 2026" means October or later for your pharmacy.

What did the pathfinder programme show?

That community pharmacists can prescribe safely at scale, but only where governance, supervision and IT are in place. NHS England's Independent Prescribing Pathfinder Programme ran across integrated care boards until it formally concluded on 31 December 2025. By the end of October 2025 the sites had, in NHS England's words, "delivered over 33,000 patient consultations across 164 pharmacy sites, with more than 59% resulting in prescribing interventions". ICBs that kept sites running to March 2026 received £1,500 per site.

The independent evaluation by the University of Manchester and ICF was published on 8 January 2026. It named five things the model depends on: clinical governance, clinical supervision, the right skill mix, digital infrastructure and a financially viable funding model. It found some insurers unfamiliar with community pharmacy prescribing, read-only access to the GP record limiting what prescribers could do, and clinical supervision scarce in community pharmacy. Each of those is a cost the £525 has to stretch across.

The pathfinders also tested long-term condition models, including cardiovascular and respiratory care. None of those is in the national service. The 2026/27 offer is deliberately narrow: acute conditions and contraception, where Pharmacy First already has the workflow, plus a handful of new acute pathways. Whether the service grows beyond that is a question for the reform programme CPE and the government have agreed to run.

Key takeaways

FAQs